Crohn's Disease

Exposure to biologics, thiopurines or combination therapy for inflammatory bowel disease during pregnancy did not increase maternal or infant adverse events at birth or in 1-year of life, according to a study published in Gastroenterology.

In March 2020, there was so much we did not know about COVID-19 and how it would impact the world of gastroenterology. Were our patients at risk? How long would endoscopy be disrupted? When will things be normal again?

Serological responses from patients with inflammatory bowel disease on biologic therapies had 100% seropositivity after two doses of the COVID-19 mRNA vaccinations, according to a study published in Gastroenterology.

Patients with perianal Crohn’s disease had worsened disease outcomes compared with patients with Crohn’s disease alone, according to research published in Clinical Gastroenterology and Hepatology.

Fecal dipeptidyl peptidase-4 may be used as a noninvasive biomarker in patients with inflammatory bowel disease, according to research published in Clinical and Translational Gastroenterology.

Patients with Crohn’s disease who were biologic naive had similar rates of clinical remission and speed of onset whether they were treated with Remicade or Stelara, according to study results.

Patients with Crohn’s disease who were biologic naive had similar rates of clinical remission and speed of onset whether they were treated with Remicade or Stelara, according to study results.

Simultaneous use of biologic agents in combination or with Xeljanz may be a viable treatment option for highly selected, refractory patients with inflammatory bowel disease, according to study results.

Researchers found that specific foods and nutrients correlated with species known to have mucosal protection and anti-inflammatory effects, according to data published in Gut.

These reports include new research on the impact of greenspace exposure, gluten intake and yeast commonly found in cheese.